ライフサイエンスコーパス: primary effusion lymphoma

1 open reading frames shown to be expressed in primary effusion lymphoma.

2 1 protein is expressed in Kaposi sarcoma and primary effusion lymphoma.

3 rus) has been linked to Kaposi's sarcoma and primary effusion lymphoma.

4 at induces Kaposi's sarcoma and AIDS-related primary effusion lymphoma.

5 activity and contribute to the phenotype of primary effusion lymphoma.

6 ric Castleman's disease, and AIDS-associated primary effusion lymphoma.

7 lex virus ICP27 genes, from an HHV8-infected primary effusion lymphoma.

8 ly etiological agent of Kaposi's sarcoma and primary effusion lymphoma.

9 iated with HHV8 include Kaposi's sarcoma and primary effusion lymphoma.

10 Kaposi's sarcoma and a rare B cell lymphoma, primary effusion lymphoma.

11 orders, multicentric Castleman's disease and primary effusion lymphoma.

12 rpesvirus (KSHV) causes Kaposi's sarcoma and primary effusion lymphoma.

13 S, multicentric Castleman disease (MCD), and primary effusion lymphoma.

14 suppression, including Kaposi's sarcoma and primary effusion lymphoma.

15 ng AIDS-associated neoplasms, such as KS and primary-effusion lymphoma.

16 umors, multicentric Castleman's disease, and primary effusion lymphomas.

17 hogenesis of Kaposi's sarcoma, as well as in primary effusion lymphomas.

18 lymphoma subtypes such as plasmablastic and primary effusion lymphomas.

19 to the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas.

20 (KS), multicentric Castleman's disease, and primary effusion lymphomas.

21 pathogenesis of Kaposi's sarcoma and B cell primary effusion lymphomas.

22 in the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas.

23 in KS lesions and in cell lines derived from primary effusion lymphomas.

24 sociations with KS, Castleman's disease, and primary effusion lymphomas.

25 ; 4 of 11 AIDS-Burkitt lymphoma; 4 of 6 AIDS-primary effusion lymphoma; 1 of 4 AIDS-primary central n

26 ifest with Kaposi's sarcoma or less commonly primary effusion lymphoma and Castleman's disease; these

27 signaling in HHV-8 productive replication in primary effusion lymphoma and endothelial cells.

28 k6 complex exists in cell lines derived from primary effusion lymphoma and in Kaposi's sarcoma, this

29 present in all cases of Kaposi's sarcoma and primary effusion lymphoma and in some cases of multicent

30 t is implicated in B cell neoplasias such as primary effusion lymphoma and multicentric Castleman dis

31 mmaherpesvirus that has been associated with primary effusion lymphoma and multicentric Castleman's d

32 might also contribute to the pathogenesis of primary effusion lymphoma and multicentric Castleman's d

33 , and to hematologic malignancies, including primary effusion lymphoma and multicentric Castleman's d

34 cal factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's d

35 mplicated in Kaposi's sarcoma, as well as in primary effusion lymphoma and multicentric Castleman's d

36 a and with two lymphoproliferatve disorders, primary effusion lymphoma and multicentric Castleman's d

37 ther lymphoproliferative diseases, including primary effusion lymphoma and multicentric Castleman's d

38 ved in the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma and some cases of multicentric

39 ith two B-cell lymphoproliferative diseases, primary effusion lymphoma and the plasmablastic form of

40 ays showed consistent expression of vIL-6 in primary effusion lymphomas and in a case of human immuno

41 Most primary effusion lymphomas and Kaposi's sarcoma tumor ce

42 to the development of Kaposi's sarcoma (KS), primary effusion lymphoma, and a proportion of Castleman

43 endemic and AIDS-associated Kaposi sarcoma, primary effusion lymphoma, and Castleman disease.

44 Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease are t

45 aherpesvirus implicated in Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease, enco

46 erpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and Castleman's disease.

47 ributing to development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman de

48 ent human malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman di

49 lignancies, including Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's

50 an malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

51 ogic agent associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

52 is the etiologic agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

53 e different human cancers: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

54 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

55 ssociated with three human malignancies, KS, primary effusion lymphoma, and multicentric Castleman's

56 e etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman's

57 /HHV-8) has been linked to Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

58 ) has been associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

59 (KSHV) is associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

60 (KSHV) is associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

61 (HHV-8) is associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

62 d with the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

63 stently identified in Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's

64 nked to the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

65 ed with the development of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

66 an malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's

67 us is the etiologic agent of Kaposi sarcoma, primary effusion lymphoma, and plasma cell-type multicen

68 is the infectious cause of Kaposi's sarcoma, primary effusion lymphoma, and plasmablastic multicentri

69 induction and maintenance of Kaposi sarcoma, primary effusion lymphoma, and some cases of Castleman d

70 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma, and some forms of multicentri

71 is etiologically linked to Kaposi's sarcoma, primary effusion lymphomas, and multicentric Castleman's

72 ted Kaposi's sarcoma (KS), body cavity-based primary effusion lymphomas, and multicentric Castleman's

73 tion using antagomirs in KSHV-infected human primary effusion lymphoma B cells resulted in derepressi

74 ion was explored by studying 2 KSHV-infected primary effusion lymphoma B-cell lines (BC-3 and BCBL-1)

75 ctor activity was expressed in KSHV-infected primary effusion lymphoma BCBL1 cells (TRExBCBL1-hNIC) i

76 rly, transient expression of siRNAs into the primary effusion lymphoma cell line BCBL-1 caused a subs

77 Infection of a primary effusion lymphoma cell line by vesicular stomati

78 In BC-1, a primary effusion lymphoma cell line that is dually infec

79 by diluting KSHV DNA from the KS-1 cells (a primary effusion lymphoma cell line which is estimated t

80 lytic KSHV replication in two KSHV-infected primary effusion lymphoma cell lines (BC-3 and BC-1) and

81 K3+1 expression in a subset of KSHV-infected primary effusion lymphoma cell lines as a consequence of

82 SHV mature microRNA expression in a panel of primary effusion lymphoma cell lines by real-time RT-PCR

83 In vitro analysis of KSHV-infected primary effusion lymphoma cell lines in the presence of

84 as well as cocultivation with HHV-8-positive primary effusion lymphoma cell lines, activated the lacZ

85 rcoma-associated herpesvirus (KSHV)-infected primary effusion lymphoma cell lines, and its expression

86 As in all primary effusion lymphoma cell lines, there is a low lev

87 viral gene expression is similar to that of primary effusion lymphoma cell lines.

88 tetradecanoyl phorbol acetate-treated JSC-1 primary effusion lymphoma cell lysate, the levels of ass

89 VEC) infected through coculture with induced primary effusion lymphoma cells and telomerase-immortali

90 virus (KSHV) maintains a latent infection in primary effusion lymphoma cells but can be induced to en

91 in vitro and in vivo, and Kaposi sarcoma and primary effusion lymphoma cells demonstrate high levels

92 nvasiveness, as well as colony formation, by primary effusion lymphoma cells derived from human tumor

93 shown to be important for the maintenance of primary effusion lymphoma cells in culture and is chroni

94 Treatment of primary effusion lymphoma cells latently infected by Kap

95 tic replication of KSHV in latently infected primary effusion lymphoma cells via beta-adrenergic acti

96 nd to LANA in transfected cells and in BCBL1 primary effusion lymphoma cells was found to be enriched

97 -I expression on EC and MHC-II expression on primary effusion lymphoma cells, but its effects on EC M

98 tion and survival of HHV-8 latently infected primary effusion lymphoma cells.

99 sodium butyrate and trichostatin A, in HH-B2 primary effusion lymphoma cells.

100 ey role in the survival and proliferation of primary effusion lymphoma cells.

101 ed a gene expression system in KSHV-infected primary effusion lymphoma cells.

102 he early lytic cycle of viral replication in primary effusion lymphoma cells.

103 istronic v-FLIP transcripts in KSHV-infected primary effusion lymphoma cells.

104 ISG induction and KSHV lytic reactivation in primary effusion lymphoma cells.

105 refore, we tested a BCL2 family inhibitor in primary effusion lymphoma cells.

106 dentified the teHsp90 interactome in KSHV(+) primary effusion lymphoma cells.

107 of KSHV lytic reactivation in KSHV-positive primary effusion lymphoma cells.

108 , and we administered them directly to human primary-effusion lymphoma cells infected with KSHV.

109 issues of patients with Kaposi's sarcoma and primary effusion lymphomas, contains a gene that encodes

110 Human primary effusion lymphoma-derived CD14+ cell-injected SC

111 containing the remaining 2 microRNAs from 5 primary effusion lymphoma-derived cell lines and from 17

112 NAs, we cloned small RNAs from KSHV-positive primary effusion lymphoma-derived cells and endothelial

113 in the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas, encodes a G protein-coupled

114 he etiological agent of Kaposi's sarcoma and primary effusion lymphoma, has developed a unique mechan

115 While attempting to establish primary effusion lymphoma in severe combined immunodefic

116 es Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients.

117 ymphocytes, and human herpesvirus 8-positive primary effusion lymphoma, inhibitors of Syk, MEK, and,

118 This novel antiviral approach to Primary Effusion lymphomas is targeted and may represent

119 KSHV causes primary effusion lymphomas, multicentric Castleman's dis

120 Primary effusion lymphoma or body cavity-based lymphoma

121 bly range from Kaposi sarcoma (KS) to either primary effusion lymphoma or multicentric Castleman dise

122 family) were significantly down-regulated in primary effusion lymphoma (PEL) and in Kaposi sarcoma (K

123 of immunocompromised individuals, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS

124 tive disorders of these cells manifesting as primary effusion lymphoma (PEL) and multicentric Castlem

125 and two other lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castlem

126 B cell lymphoproliferative diseases, namely primary effusion lymphoma (PEL) and multicentric Castlem

127 ontribute to B-cell disorders, which include primary effusion lymphoma (PEL) and multicentric Castlem

128 ifferent human cancers, Kaposi sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castlem

129 Primary effusion lymphoma (PEL) and myeloma are lymphoid

130 h KS, in 6 (85.7%) of 7 HIV(+) patients with primary effusion lymphoma (PEL) and/or multicentric Cast

131 Primary effusion lymphoma (PEL) appears as an AIDS-defin

132 ells of classical Hodgkin lymphoma (cHL) and primary effusion lymphoma (PEL) are derived from germina

133 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) are two well-known infla

134 wn of miR-K1 in latently KSHV-infected human primary effusion lymphoma (PEL) B cells revealed a derep

135 NA-1) protein, and in KSHV latently infected primary effusion lymphoma (PEL) BCBL-1 and BC-3 cells.

136 A primary effusion lymphoma (PEL) cell line, JSC-1, that y

137 In HH-B2, a newly established primary effusion lymphoma (PEL) cell line, KSHV ORF50 be

138 93 cells as well as the KSHV-infected BCBL-1 primary effusion lymphoma (PEL) cell line.

139 latency-associated nuclear antigen (LANA) in primary effusion lymphoma (PEL) cell lines and also incr

140 induction of lytic viral replication in both primary effusion lymphoma (PEL) cell lines and KS tumors

141 Primary effusion lymphoma (PEL) cell lines infected with

142 quences revealed that c-Myc in KSHV-positive primary effusion lymphoma (PEL) cell lines is wild type

143 d the expression of vGCR mRNA and protein in primary effusion lymphoma (PEL) cell lines, PEL and mult

144 cle can be induced in rare latently infected primary effusion lymphoma (PEL) cell lines, the ability

145 by chemicals that induce the lytic cycle in primary effusion lymphoma (PEL) cell lines.

146 Myc knockdown inhibited primary effusion lymphoma (PEL) cell proliferation throu

147 negatively impacting HHV-8 latently infected primary effusion lymphoma (PEL) cell viability and react

148 Primary effusion lymphoma (PEL) cells are predominantly

149 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) cells are predominantly

150 nce-based knockdown of KAP1 in KSHV-infected primary effusion lymphoma (PEL) cells disrupted viral ep

151 Depletion of RPS6 from primary effusion lymphoma (PEL) cells dramatically decre

152 Examination of primary effusion lymphoma (PEL) cells found increased le

153 Primary effusion lymphoma (PEL) cells harbor Kaposi's sa

154 In primary effusion lymphoma (PEL) cells infected with late

155 e that vFLIP in BCBL-1 endogenously infected primary effusion lymphoma (PEL) cells mediates JNK/AP1 a

156 tance of iASPP to KSHV-infected-cell growth, primary effusion lymphoma (PEL) cells were treated with

157 epetitive region of LNA, detected antigen in primary effusion lymphoma (PEL) cells, and precipitated

158 rantly accumulated in KSHV latently infected primary effusion lymphoma (PEL) cells, as well as HEK293

159 ation of these proteins was also detected in primary effusion lymphoma (PEL) cells, as well as in a c

160 virus (KSHV) maintains a latent infection in primary effusion lymphoma (PEL) cells, but treatment wit

161 In primary effusion lymphoma (PEL) cells, vIL-6 is expresse

162 i's sarcoma-associated herpesvirus (KSHV) in primary effusion lymphoma (PEL) cells.

163 ces in tetradecanoyl phorbol acetate-induced primary effusion lymphoma (PEL) cells.

164 angiogenesis and the survival and growth of primary effusion lymphoma (PEL) cells.

165 KSHV and Epstein-Barr virus-coinfected JSC1 primary effusion lymphoma (PEL) cells.

166 s of the viral cytokine in latently infected primary effusion lymphoma (PEL) cells.

167 etected in KS lesions and in KSHV-associated primary effusion lymphoma (PEL) cells.

168 ctivation, and proliferation of BCR-negative primary effusion lymphoma (PEL) cells.

169 Primary effusion lymphoma (PEL) constitutes a subset of

170 ts low-level expression in latently infected primary effusion lymphoma (PEL) cultures, in the absence

171 this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are r

172 man herpesvirus 8) has been linked to KS and primary effusion lymphoma (PEL) in immunocompromised ind

173 rus) has been linked to Kaposi's sarcoma and primary effusion lymphoma (PEL) in immunocompromised ind

174 e (RNAi) to inhibit the growth of a model of primary effusion lymphoma (PEL) in vitro and in vivo.

175 Primary effusion lymphoma (PEL) is a B-cell lymphoma in

176 Primary effusion lymphoma (PEL) is a diffuse-large B-cel

177 Primary effusion lymphoma (PEL) is a distinct clinicopat

178 Primary effusion lymphoma (PEL) is a distinct type of B-

179 Primary effusion lymphoma (PEL) is a distinct type of ly

180 Primary effusion lymphoma (PEL) is a highly aggressive B

181 Primary effusion lymphoma (PEL) is a largely incurable m

182 Primary effusion lymphoma (PEL) is a lymphogenic disorde

183 Primary effusion lymphoma (PEL) is a non-Hodgkin's B-cel

184 Primary effusion lymphoma (PEL) is a rare B-cell lymphom

185 Primary effusion lymphoma (PEL) is a rare B-cell neoplas

186 Primary effusion lymphoma (PEL) is a rare form of aggres

187 Primary effusion lymphoma (PEL) is a rare subtype of non

188 human B-cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique subset that

189 Primary effusion lymphoma (PEL) is an aggressive B-cell

190 Primary effusion lymphoma (PEL) is an aggressive form of

191 Primary effusion lymphoma (PEL) is an aggressive subtype

192 Primary effusion lymphoma (PEL) is an aggressive type of

193 Primary effusion lymphoma (PEL) is an AIDS-defining canc

194 AIDS-related primary effusion lymphoma (PEL) is an HIV-associated mal

195 The role of p53 in primary effusion lymphoma (PEL) is complicated.

196 ations, the vIRF3-expressing KSHV-associated primary effusion lymphoma (PEL) lines are generally resi

197 ads in molecular pathogenesis, AIDS-defining primary effusion lymphoma (PEL) remains a fatal malignan

198 -related human herpesvirus type 8-associated primary effusion lymphoma (PEL) responds poorly to chemo

199 cell lines and 6 Kaposi's sarcoma (KS) and 4 primary effusion lymphoma (PEL) tumor samples from the U

200 vital for the survival and proliferation of primary effusion lymphoma (PEL), an aggressive malignanc

201 KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also co

202 (KSHV) is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of Castleman

203 the causative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multice

204 s the etiological agent of Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

205 V) is associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

206 etiologically linked to Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

207 herpesvirus 8, is an etiologic agent of KS, primary effusion lymphoma (PEL), and multicentric Castle

208 cally associated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

209 pesvirus is linked to Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

210 and -unrelated cases of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

211 ed herpesvirus (KSHV) is associated with KS, primary effusion lymphoma (PEL), and multicentric Castle

212 fection is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

213 ibutor to virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

214 ed in the etiology of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

215 to the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

216 oliferative diseases: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

217 fection is associated with Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

218 veral neoplastic diseases: Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

219 ing region of KSHV from Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castle

220 vities to HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castle

221 uding diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), and multiple myeloma (M

222 Certain lymphomas in AIDS patients, such as primary effusion lymphoma (PEL), are closely associated

223 ed tumors, such as Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), are of endothelial and

224 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL), defective KSHV has not

225 V), a virus linked to malignancies including primary effusion lymphoma (PEL), encodes 12 miRNA genes,

226 th 3 distinct lymphoproliferative disorders: primary effusion lymphoma (PEL), multicentric Castleman

227 herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL), multicentric Castleman'

228 ammatory protein 1A (vMIP-1A) and vMIP-1B in primary effusion lymphoma (PEL)-derived cell lines and e

229 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

230 c agent associated with Kaposi's sarcoma and primary effusion lymphoma (PEL).

231 cells in patients with Kaposi's sarcoma and primary effusion lymphoma (PEL).

232 tiologic agent for Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

233 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

234 causative agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

235 ociated with several malignancies, including primary effusion lymphoma (PEL).

236 tumors, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

237 responsible for Kaposi's sarcoma as well as primary effusion lymphoma (PEL).

238 that causes Kaposi sarcoma and AIDS-related primary effusion lymphoma (PEL).

239 lso linked to the rare B-cell tumor known as primary effusion lymphoma (PEL).

240 ls and in HHV-8-associated tumors, including primary effusion lymphoma (PEL).

241 cts human lymphocytes and is associated with primary effusion lymphoma (PEL).

242 n's disease (CD), Kaposi's sarcoma (KS), and primary effusion lymphoma (PEL).

243 nancies, including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

244 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

245 multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL).

246 malignancies, including Kaposi's sarcoma and primary effusion lymphoma (PEL).

247 ts with AIDS-related Kaposi sarcoma (KS) and primary effusion lymphoma (PEL).

248 cy Kaposi sarcoma, or the B-cell malignancy, primary effusion lymphoma (PEL).

249 multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL).

250 rs, multicentric Castleman disease (MCD) and primary effusion lymphoma (PEL).

251 herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).

252 functions of ANG in KSHV-positive (KSHV(+)) primary effusion lymphoma (PEL/BCBL) cells.

253 th two additional AIDS-related malignancies: primary effusion lymphomas (PEL) and multicentric Castle

254 Primary effusion lymphomas (PEL) are associated with hum

255 The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected w

256 human immunodeficiency virus (HIV)- related primary effusion lymphomas (PEL), a sensitive enzyme-lin

257 sociated herpesvirus (KSHV) is linked to KS, primary effusion lymphomas (PEL), and a subset of multic

258 lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related

259 ) are found together in approximately 80% of primary effusion lymphomas (PEL), but their contribution

260 that these malignant lymphomas be designated primary effusion lymphomas (PEL), rather than body cavit

261 ciated with Kaposi's sarcoma (KS) as well as primary effusion lymphomas (PEL).

262 n Human Herpes Virus Type 8 (HHV-8) positive Primary Effusion Lymphomas (PEL).

263 irus (KSHV or HHV8) sequences are present in primary effusion lymphomas (PEL).

264 ma-associated herpes virus (KSHV/HHV-8), and primary effusion lymphomas (PEL).

265 called body cavity-based lymphomas (BCBL) or primary effusion lymphomas (PEL).

266 known to be an etiologic force behind KS and primary-effusion lymphoma (PEL).

267 Primary effusion lymphomas (PELs) are specifically assoc

268 Primary effusion lymphomas (PELs) associated with infect

269 KSHV-associated primary effusion lymphomas (PELs) secrete high levels of

270 d mature miRNA levels for the largest set of primary effusion lymphomas (PELs) to date.

271 of Kaposi's sarcoma (KS), body-cavity-based, primary effusion lymphomas (PELs), and a subset of Castl

272 rpesvirus (KSHV) latently infects KS tumors, primary effusion lymphomas (PELs), and PEL cell lines.

273 n herpesvirus 8) latently infects KS tumors, primary effusion lymphomas (PELs), and PEL cell lines.

274 Primary effusion lymphomas (PELs), which are rare lympho

275 with numerous human malignancies, including primary effusion lymphomas (PELs).

276 oma-associated herpesvirus (KSHV/HHV-8), and primary effusion lymphomas (PELs).

277 , as well as a rare form of B cell lymphoma (primary effusion lymphoma) primarily observed in HIV-inf

278 present in all cases of Kaposi's sarcoma and primary effusion lymphoma, provide opportunities for sel

279 n Kaposi sarcoma herpesvirus (KSHV)-infected primary effusion lymphoma through down-regulation of the

280 gher in latently infected cells derived from primary effusion lymphomas; thus, it appears that HHV-8

281 erm body-cavity-based lymphoma with the term primary effusion lymphoma, which describes these non-Hod

282 ly associated with Kaposi's sarcoma (KS) and primary effusion lymphoma, with viral genomes present in